



CERTIFICATE OF MAILING		
I hereby certify that the correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, Washington, D.C. 20231.		
Typed or Printed Name	Cindy Hoang	
Signature	Date	
RESPONSE TO RESTRICTION REQUIREMENT Address to: Commissioner for Patents Washington, D.C. 20231	Attorney Docket (Confirmation No.)	UCAL217 7367
	First Named Inventor	Y. Huang
	Application Number	10/033,526
	Filing Date	November 2, 2001
	Group Art Unit	1647
	Examiner Name	C.J. Nichols
	Title:	Methods of treating disorders related to apoE

RECEIVED
NOV 21 2002
TECH CENTER 1600/2900
#7
12/4/02

Sir:

This is in response to the Restriction Requirement dated September 11, 2002. The Restriction Requirement set forth a one-month time period for response, making a response due on or before November 11, 2002. Accordingly, this response is timely filed.

I. REMARKS

RESTRICTION REQUIREMENT

In the Restriction Requirement, the Office Action made two restriction requirements, as follows:

1) Claim groups

The Office Action required election of one of the following groups of claims:

- Group I: Claims 1-6, 23-24, 28, and 31, drawn to a method of inhibiting formation of neurofibrillary tangles in an individual said method comprising reducing formation of a carboxyl-truncated form of apoE;
- Group II: Claims 7-11, drawn to a transgenic non-human animal;
- Group III: Claims 12-16, drawn to a method of screening for biologically active agents;
- Group IV: Claims 17-20, drawn to an isolated cell comprising a nucleic acid molecule that comprises a nucleotide sequence that encodes a carboxyl-terminal truncated form of apoE;
- Group V: Claims 21 and 22, drawn to a method of inhibiting formation of neurofibrillary tangles in an individual, the method comprising inhibiting interaction of carboxyl-terminal truncated form of apoE with other components of neurofibrillary tangle;
- Group VI: Claim 26, drawn to a method of treating Alzheimer's disease the method of comprising assaying for the presence of carboxyl-terminal truncated apoE in a neuronal cell and